2Moll R,Schile DL,Franke WW.Identification of prote in IT of the intestinal cytoskeleton as a novel type I cytokeration with unusual properties and expression patterns[J].J Cell Biot,2008,111(8):567-580.
3Dohm oto K,Hojo S,Fujita I,et al.Mechanism of the release of CYFRA21-1 in human lung cancer cell lines[J].Lung Cancer,2007,30(1):55.
4Sheard MA,Vojetesek B,Simickova M,et al.Release of cytokeratin -18 and 19 fragments(TPS and CYFRA21-1) into the extracellular space during apoptosis[J].J Cell Biochem,2008,5(4):670.
8Pariente JL,Bordenave L,Michel PH,et al.Initial evaluation of CYFRA21-1 diagnostic performance as a urinary maker in bladder transitional cell carcinoma[J].J Urol,2007,158(11):338.
9Morita T,Kikuchi T,Hashimoto S,et al.Cytokeratin-19 fragment(CYFRA21-1) in bladder cancer[J].Eur Urol,1997,32(10):237-244.
10Senga Y,Kimura GM,Hattori T,et a1.Clinical evaluation of soluble Cytokeratin-19 fragments(CYFRA21-I) in serum and urine of patients with bladder cancer[J].Urology,1996,48(4):703.
3Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumor markers in patients with non-small lung cancer: a prospective study of 116 patients. Eur J Cancer, 1997,33(3):385-391.
4Gaarenstroom KN, Bonfrer JM, Korse CM,et al. Value of Cyfra21-1 ,TPA and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.Anticancer Res, 1997,17(4B) :2955-2958.
6Nakata B,Chung YS, Kato Y,et al.Clinical significance of serum Cyfra21-1 in gastric cancer. Br J Cancer, 1996,73(12) : 1529-1532.
7Moll R,Franke WW,Schiller DL,et al. The catalog of human cytokeratins:patterns of expression in normal epithelial, tumors and cultured cells. Cell,1982,31 : 11-24.
8Ychou M, Khemissa-Akouz F, Kramar A, et al. A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma. Bull Cancer, 2001, 88:1023-1027.
9Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 detemdnation in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer, 2000, 89:1413-1417.
10Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer, Lancet, 2002,359:572-577.
3Kashiwabara K, Kishi K, Nakamura H, et al. Mechanism of increased serum cytokerafin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure [J]. Intern Med, 1998, 37 (11) : 917-921.
